Pathwork Diagnostics
Originally published Dec. 20.
The Tissue of Origin Test, a microarray-based gene expression assay commercialized by the defunct firm Pathwork Diagnostics, may soon become available again.
Response Genetics Buys Assets of Pathwork Diagnostics
NEW YORK (GenomeWeb News) – Response Genetics today announced it has acquired the "key assets" of Pathwork Diagnostics, including its US Food and Drug Administration-cleared and Medicare-reimbursed test for diagnosing metastatic, poorly differentiated, and undifferentiated cancer.
Samsung Electronics of Seoul, South Korea, has received US Patent No. 8,469,492, "Method of printing droplet using capillary electric charge concentration." The method relies on a capillary nozzle that consists of a back end and a front end.
Pathwork Diagnostics has gone out of business as of April 2, PGx Reporter has learned.
Feb 10, 2012
Jan 10, 2012
Nov 8, 2011
Mar 28, 2011
Pathwork Diagnostics Gets CAP Accreditation
Mar 15, 2011
Jun 29, 2010
IP Roundup: Jun 29, 2010
Premium
Jun 23, 2010
Jun 15, 2010